Reference | Source | Indication | No of patients (patient-years) | Incidence rate per 1000 patient-years (95% CI) | Risk estimate (95% CI) | Standardised incidence ratio (95% CI) |
---|---|---|---|---|---|---|
All-site malignancies | ||||||
Watson et al (2006)51 | BSRBR | RA | 9999 (19 070) | 8.6 (7.4 to 10.0) | 0.7 (0.4 to 1.2)* | NR |
Greenberg et al (2007)19 | CORRONA | RA | 4651 (8690) | 7.48 (NR) | 1.05 (0.73 to 1.51)* | NR |
Wolfe and Michaud (2007)31† | NDBRD | RA | 5257 (NR) | NR | 1.0 (0.8 to 1.2)‡ | 1.0 (1.0 to 1.1)§ |
Abasolo et al (2008)20 | BIOBADASER | RA | 4529 (11 758) | 6.0 (4.7 to 7.5) | 0.92 (0.41 to 2.04)* | NR |
Askling et al (2009)15 | ARTIS | RA | 6366 (25 693) | 9.34 (8.19 to 10.60) | 1.00 (0.87 to 1.17)¶ | 0.9 (0.7 to 1.2)** |
Du Pan et al (2009)14 | SCQM-RA | RA | 2364 (3867) | 3.88 (NR) | NR | NR |
Gibofsky et al (2009)18 | RADIUS | RA | 2206 (3509) | 7 (5 to 11) | 0.6 (0.3 to 1.6)§ | NR |
Pallavicini et al (2010)24 | LORHEN | RA | 1064 (2069) | 8.7 (4.68 to 12.72) | NR | 0.94 (0.55 to 1.48)†† |
1.09 (0.64 to 1.72)‡‡ | ||||||
Strangfeld et al (2010)17§§ | RABBIT | RA | 3346 (12 198) | 5.1 (3.7 to 6.9) | 0.70 (0.44 to 1.12)¶¶ | 0.75 (0.54 to 1.01) |
Haematopoietic malignancies | ||||||
Askling et al (2005)41 | ARTIS | RA | 4160 (9715) | 1.13 (NR) | NR | 2.1 (1.1 to 3.8) |
Greenberg et al (2007)19 | CORRONA | RA | 4651 (8690) | 0.69 (NR) | 0.76 (0.26 to 2.29)* | NR |
Pallavicini et al (2010)24 | LOHREN | RA | 1064 (2069) | NR | NR | 4.08 (1.32 to 9.53)†† |
4.07 (1.31 to 9.49)‡‡ | ||||||
Leukaemia | ||||||
Askling et al (2005)41*** | ARTIS | RA | 4160 (9715) | 0.21 (NR) | NR | 2.0 (0.2 to 7.3) |
Wolfe and Michaud (2007)31† | NDBRD | RA | 5257 (NR) | NR | 1.2 (0.5 to 3.1)‡ | NR |
Lymphoma | ||||||
Wolfe and Michaud (2004)21 | NDBRD | RA | 8614 (10 012) | 1.4 (NR) | NR | 2.9 (1.7 to 4.9) |
Greenberg et al (2007)19 | CORRONA | RA | 4651 (8690) | 0.58 (NR) | 0.74 (0.23 to 2.45)* | NR |
Wolfe and Michaud (2007)22 | NDBRD | RA | 10 834 (NR) | NR | 1.0 (0.6 to 1.8)‡ | NR |
Askling et al (2009)23 | ARTIS | RA | 6604 (29 981) | 0.96 (0.63 to 1.41) | 1.35 (0.82 to 2.11)¶ | 2.72 (1.82 to 4.08)††† |
Pallavicini et al (2010)24 | LOHREN | RA | 1064 (2069) | 3.38 (0.88 to 5.89) | NR | 5.99 (1.61 to 15.35)†† |
4.98 (1.34 to 12.74)‡‡ | ||||||
Mariette et al (2010)25 | RATIO | All | NR (57 711) | 0.42 (0.07 to 0.78) | NR | 2.4 (1.7 to 3.2) |
RA‡‡‡ | NR | NR | NR | 2.3 (1.6 to 3.3) | ||
Prior malignancies | ||||||
Dixon (2010)16 | BSRBR | RA | 177 (NR) | 25.3 (13.4 to 43.2)§§§ | 0.58 (0.23 to 1.43)* | NR |
Strangfeld et al (2010)17¶¶¶ | RABBIT | RA | 72 (198) | 45.5 (20.8 to 86.3) | 1.4 (0.5 to 5.5)* | NR |
Melanoma | ||||||
Greenberg et al (2007)19 | CORRONA | RA | 4651 (8690) | 0.35 (NR) | NR | NA§§§§ |
Wolfe and Michaud (2007)31† | NDBRD | RA | 6238 (NR) | NR | 2.3 (0.9 to 5.4)‡**** | NR |
Askling (2009)28 | ARTIS | RA | 6604 (NR) | NR | 1.7 (1.0 to 2.9)¶ | NR |
NMSC | ||||||
Greenberg et al (2007)19 | CORRONA | RA | 4651 (8690) | 2.3 (NR) | 1.83 (0.85 to 3.93)* | NR |
Wolfe and Michaud (2007)31† | NDBRD | RA | 5257 (NR) | NR | 1.5 (1.2 to 1.8)‡ | NR |
1394 (NR)§§§ | NR | 2.3 (0.9 to 5.4)‡†††† | ||||
Mercer et al (2009)30‡‡‡‡ | BSRBR | RA | 11 757 (NR) | 3.5 (2.9 to 4.1) | Crude 1.0 (0.6 to 1.6)¶¶ | NR |
Adj 1.7 (0.9 to 3.4) | ||||||
Askling (2009)28 | ARTIS | RA | 6604 (NR) | NR | 1.2 (0.8 to 2.0)¶¶¶¶ | NR |
↵* Adjusted incidence rate ratio.
↵† Includes Anakinra data.
↵‡ OR.
↵§ Excludes NMSC.
↵¶ RR.
↵** Solid malignancies.
↵†† Compared with general population data in the Milan Cancer report.
↵‡‡ Compared with general population data in the Varese Cancer Registry database.
↵§§ Patients without previous malignancy.
↵¶¶ HR.
↵*** Excluding chronic lymphocytic leukaemia.
↵††† Against general population.
↵‡‡‡ RA data included in the analyses.
↵§§§ Against DMARD population.
¶¶¶ Patients with previous malignancies only.
↵**** 3+ years since entry into registry.
↵†††† Melanoma cases.
↵‡‡‡‡ Patients with no previous NMSC.
↵§§§§ Three occurrences in TNFi cohort but zero occurrences in DMARD cohort.
↵¶¶¶¶ Squamous cell skin cancer.
DMARD, disease-modifying antirheumatic drug; NMSC, non-melanoma skin cancer; NR, not reported; RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor.